Associate Professor Elgene LimGarvan Institute of Medical ResearchCancer Council NSW Funding: $450,000Funding duration: 2017-2019
Estrogen is a female hormone that promotes breast cancer growth, and drugs that counteract this effect (known as antiestrogenic drugs) are used to treat the disease. One such drug is tamoxifen, and the research team has discovered that another hormone, progesterone, enhances the antiestrogenic effect of Tamoxifen.
This project will provide the critical clinical evidence on the effectiveness of adding progesterone to antiestrogenic therapies in patients with early stage breast cancer.
The researchers predict that this combination treatment will be more effective than the current standard of care in stopping tumour growth and improving patient outcomes. The results of this study will allow the researchers to move closer to initiating a clinical trial on a larger group of patients.